Generic Sohonos Availability
Last updated on Jan 8, 2025.
Sohonos is a brand name of palovarotene, approved by the FDA in the following formulation(s):
SOHONOS (palovarotene - capsule;oral)
-
Manufacturer: IPSEN
Approval date: August 16, 2023
Strength(s): 1MG [RLD], 1.5MG [RLD], 2.5MG [RLD], 5MG [RLD], 10MG [RLD]
Has a generic version of Sohonos been approved?
No. There is currently no therapeutically equivalent version of Sohonos available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sohonos. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Composition and method for muscle repair and regeneration
Patent 10,292,954
Issued: May 21, 2019
Inventor(s): Iwamoto Masahiro & Pacifici Maurizio
Assignee(s): Thomas Jefferson UniversityThe invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Patent expiration dates:
- August 31, 2031✓
- August 31, 2031
-
Methods for treating heterotopic ossification
Patent 10,864,194
Issued: December 15, 2020
Inventor(s): Desjardins Clarissa & Grogan Donna Roy & Packman Jeffrey Neal & Harnett Mark
Assignee(s): Clementia Pharmaceuticals Inc.The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
Patent expiration dates:
- June 8, 2037✓
- June 8, 2037
-
Patent 11,622,959
Patent expiration dates:
- June 8, 2037✓
- June 8, 2037
-
Patent 12,023,312
Patent expiration dates:
- August 31, 2031✓
- August 31, 2031
-
Patent 12,138,245
Patent expiration dates:
- June 8, 2037✓
- June 8, 2037
-
Composition and method for muscle repair and regeneration
Patent 9,314,439
Issued: April 19, 2016
Inventor(s): Iwamoto Masahiro & Pacifici Maurizio
Assignee(s): Thomas Jefferson UniversityThe invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Patent expiration dates:
- August 31, 2031✓
- August 31, 2031
-
Composition and method for muscle repair and regeneration
Patent 9,789,074
Issued: October 17, 2017
Inventor(s): Iwamoto Masahiro & Pacifici Maurizio
Assignee(s): Thomas Jefferson UniversityThe invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Patent expiration dates:
- August 31, 2031✓
- August 31, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 16, 2028 - NEW CHEMICAL ENTITY
- August 16, 2030 - FOR THE REDUCTION IN VOLUME OF NEW HETEROTOPIC OSSIFICATION IN ADULTS AND PEDIATRIC PATIENTS AGED 8 YEARS AND OLDER FOR FEMALES AND 10 YEARS AND OLDER FOR MALES WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
More about Sohonos (palovarotene)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.